Drugs / Oxazyme
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01127087 | May 2010 → Sep 2011 | — | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxazyme | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01127087 ↗ |
| Modality | Protein / enzyme biologic | “Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC).” NCT01127087 ↗ |
| Route | Oral | “non-systemic orally delivered drug” NCT01127087 ↗ |